Sandoz gains worldwide marketing rights to Organogenesis' Graftskin.
This article was originally published in The Gray Sheet
Executive Summary
SANDOZ' EXCLUSIVE WORLDWIDE LICENSE TO ORGANOGENESIS' GRAFTSKIN gives the Swiss pharmaceutical company its first medical device product and furthers its expansion into dermatology. The firms jointly announced Jan. 17 an agreement under which Sandoz will pay up to $37.5 mil. in exchange for global marketing rights to Graftskin, a manufactured human skin product for which a premarket approval application is pending at FDA.